United Capital Financial Advisers, LLC Galapagos Nv Transaction History

United Capital Financial Advisers, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$68.86 - $83.34 $377,903 - $457,369	-5,488 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$76.15 - $111.94 $743,604 - $1.09 Million	-9,765 Reduced 64.02%	5,488 $423,000
Q4 2020 Feb 17, 2021	SELL	$96.85 - $148.25 $665,746 - $1.02 Million	-6,874 Reduced 31.07%	15,253 $1.51 Million
Q3 2020 Nov 13, 2020	SELL	$122.47 - $213.56 $582,834 - $1.02 Million	-4,759 Reduced 17.7%	22,127 $3.14 Million
Q2 2020 Aug 13, 2020	SELL	$185.52 - $231.25 $87,008 - $108,456	-469 Reduced 1.71%	26,886 $5.3 Million
Q1 2020 May 15, 2020	BUY	$143.0 - $274.03 $3.91 Million - $7.5 Million	27,355 New	27,355 $5.36 Million

12.3M

69.1K

42.7K

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.9B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

Get notified when there are updates to the investment portfolio of United Capital Financial Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on United Capital Financial Advisers, LLC with notifications on news.